Novaremed banner3

 

Novaremed is a pharmaceutical company that utilizes a highly innovative proprietary library of small molecules to develop safer and more efficacious drugs for chronic and life-threatening diseases.

NRD135S-E1 is a first-in-class tyrosine kinase modulator for the treatment of neuropathic pain associated with diabetes.

Chairman: Ben-Zion Weiner, Ph.D.

Board members: SK Tan, Janifer Yeo-Tan, Eli Kaplan, Zvi Slonimsky, Joseph Feinstein, Benny Sidon, Yaron Yenni.